Pacritinib
Sign in to save this workspacePrimary targets: JAK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
88.64
Gini
0.452
CATDS
0.006
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Pacritinib. Strongest target: IRAK1 at 99.6% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | IRAK1 | 99.6% | 0.4% |
| 2 | TNIK | 99.2% | 0.8% |
| 3 | CLK1 | 98.8% | 1.2% |
| 4 | TYK2 | 98.8% | 1.2% |
| 5 | JAK2 | 98.4% | 1.6% |
| 6 | LCK | 98.4% | 1.6% |
| 7 | C_KIT | 98.4% | 1.6% |
| 8 | ROS_ROS1 | 98.2% | 1.8% |
| 9 | CDK9_CYCLIN_K | 98.0% | 2.0% |
| 10 | CDK9_CYCLIN_T2 | 97.9% | 2.1% |
| 11 | HIPK2 | 97.4% | 2.6% |
| 12 | HGK_MAP4K4 | 97.1% | 2.9% |
| 13 | ALK1_ACVRL1 | 96.9% | 3.1% |
| 14 | CDK9_CYCLIN_T1 | 96.8% | 3.2% |
| 15 | TRKC | 96.7% | 3.3% |
| 16 | ALK2_ACVR1 | 96.7% | 3.4% |
| 17 | PKCA | 96.4% | 3.6% |
| 18 | HIPK4 | 96.2% | 3.8% |
| 19 | FMS | 95.7% | 4.3% |
| 20 | MINK_MINK1 | 95.1% | 4.9% |
Selectivity landscape
Where Pacritinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Pacritinib.
Annotations
Sign in to read and post annotations.
Loading…